Mumbai, Oct. 7 -- Veeda Lifesciences has relaunched the process of exploring a majority stake sale in a deal that will value the company at $300-400 million and facilitate exits for its existing shareholders, three people familiar with the matter said.

"The deal will entail a majority stake sale - that could be in the range of 51% and later result in a full sale. Both private equity firms and strategics have been tapped as part of the process," the first person said, adding that negotiations are underway.

"It will be a mix of primary and secondary share sale by existing investors including CX Partners, expected to make a complete exit as part of the transaction," the second person cited above said. "It has engaged JP Morgan as an adviso...